Watch the video below, which gives an overview of the role of PCSK9 in cholesterol homeostasis through regulation of low-density lipoprotein receptor (LDLR) degradation.
Download the associated material below relating to the role of PCSK9 in the regulation of LDL-C here.
View this interactive artery showing the progression of atherosclerosis and plaque vulnerability.
Do you know the low-density lipoprotein cholesterol LDL-C levels of patients with high-risk CVD in your area? View this Cholesterol Heat Map to find out more.
Find a resource to help you empower your ASCVD patients to Aim Low and Stay Low - helping them to reach LDL-C treatment goals and stay there.
The LDL-C Action Summit is an ongoing initiative among members of the cardiovascular disease community to align around a singular mission to help patients manage LDL-C through a more coordinated effort with the ambition of bending the curve of cardiovascular disease.
Watch experts discuss current cholesterol guidelines, discharge protocol, and routine follow-up in patients with recent myocardial infarction (MI).
Watch experts discuss the healthcare professional (HCP)/patient conversation regarding the importance of LDL-C lowering for patients with recent MI.
Click here to view the American College of Cardiology/American Heart Association Task Force guidelines for the management of blood cholesterol.
Click here to view the 2019 European Society of Cardiology and European Atherosclerosis Society Task Force guidelines for the management of dyslipidemia.
Click here to view the American Association of Clinical Endocrinologists and American College of Endocrinology consensus statement for the management of dyslipidemia and prevention of cardiovascular disease.
Click here to view the American College of Cardiology's ECDP guidance on the role of non-statin therapies for LDL-C lowering in the management of ASCVD risk.
Download this overview that explains the scientific progression of atherosclerosis and ASCVD, and includes recent clinical guidelines for the treatment of patients with very high-risk ASCVD.
